In order to meet the high energy demand, a metabolic reprogramming occurs in cancer cells.
Its role is crucial in promoting tumor survival. Among the substrates in demand, oxygen is …

Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …

Multiple myeloma (MM, plasma cell myeloma) is a malignant hematologic disease
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …

Dynamic modulation of protein levels is tightly controlled in response to physiological cues.
In mammalian cells, much of the protein degradation is carried out by the ubiquitin …

Dynamic modulation and posttranslational modification of proteins are tightly controlled
biological processes that occur in response to physiological cues. One such dynamic …

Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment
over the past decade. Many PIs are being developed and evaluated in the preclinical and …

SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and
dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). This updated analysis …

Background Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has
been shown in preclinical and phase 1 studies to have antimyeloma activity. Methods In this …

Background This study compared bortezomib with high-dose dexamethasone in patients
with relapsed multiple myeloma who had received one to three previous therapies. Methods …

Newly synthesized transmembrane proteins undergo a series of steps to ensure that only
the required amount of correctly folded protein is localized to the membrane. The regulation …